Patients

Information for patients

This website is intended for US patients undergoing allogeneic stem cell transplantation for acute myeloid leukemia (AML) and their families. It provides information about the causes of graft-versus-host disease and its prevention by ex vivo T cell depletion.

Note: Are some of the words or abbreviations unfamiliar to you? Definitions of all words marked in bold can be found in the glossary.

This website is not intended to replace conversations with your healthcare team. Your doctor and other healthcare providers are your most valuable resources for answering questions about your disease and ex vivo T cell depletion as a method for graft-versus-host disease prophylaxis.

Humanitarian Device
Authorized by U.S. Federal Law for use in the treatment of patients with acute myeloid leukemia (AML) in first complete remission. The effectiveness of the device for this use has not been demonstrated.

Indications for Use
The CliniMACS® CD34 Reagent System is indicated for processing hematopoietic progenitor cells collected by apheresis (HPC, Apheresis) from an allogeneic, HLA-identical, sibling donor to obtain a CD34+ cell-enriched population for hematopoietic reconstitution following a myeloablative preparative regimen without the need for additional graft versus host disease (GVHD) prophylaxis in patients with acute myeloid leukemia (AML) in first morphologic complete remission.

Contraindications
Do not use CD34+ cells prepared with CliniMACS CD34 Reagent System in patients with known hypersensitivity to murine (mouse) proteins or iron dextran.

Rx only

You have previously chosen International as your location.
What do you want to do?

CliniMACS® CD34 Reagent System

This content is intended for US residents only.

By clicking "YES" I am confirming that I am a US resident.